Free Trial
NASDAQ:EOLS

Evolus (EOLS) Stock Price, News & Analysis

Evolus logo
$6.37 -2.54 (-28.51%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$6.33 -0.04 (-0.64%)
As of 04:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Evolus Stock (NASDAQ:EOLS)

Key Stats

Today's Range
$5.85
$6.76
50-Day Range
$6.37
$10.24
52-Week Range
$5.85
$17.82
Volume
13.69 million shs
Average Volume
1.19 million shs
Market Capitalization
$410.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.25
Consensus Rating
Moderate Buy

Company Overview

Evolus Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

EOLS MarketRank™: 

Evolus scored higher than 69% of companies evaluated by MarketBeat, and ranked 516th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Evolus has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Evolus has only been the subject of 3 research reports in the past 90 days.

  • Read more about Evolus' stock forecast and price target.
  • Earnings Growth

    Earnings for Evolus are expected to grow in the coming year, from ($0.61) to ($0.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Evolus is -6.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Evolus is -6.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Evolus has a P/B Ratio of 70.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    19.59% of the outstanding shares of Evolus have been sold short.
  • Short Interest Ratio / Days to Cover

    Evolus has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Evolus has recently increased by 5.25%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Evolus does not currently pay a dividend.

  • Dividend Growth

    Evolus does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    19.59% of the outstanding shares of Evolus have been sold short.
  • Short Interest Ratio / Days to Cover

    Evolus has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Evolus has recently increased by 5.25%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Evolus has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Evolus this week, compared to 4 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Evolus insiders have sold 713.28% more of their company's stock than they have bought. Specifically, they have bought $189,000.00 in company stock and sold $1,537,090.00 in company stock.

  • Percentage Held by Insiders

    Only 5.90% of the stock of Evolus is held by insiders.

  • Percentage Held by Institutions

    90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Evolus' insider trading history.
Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

EOLS Stock News Headlines

Needham Downgrades Evolus (EOLS)
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.
Evolus, Inc. Reports Q2 2025 Financial Results
A Look Ahead: Evolus's Earnings Forecast
Evolus, Inc. 2025 Q2 - Results - Earnings Call Presentation
See More Headlines

EOLS Stock Analysis - Frequently Asked Questions

Evolus' stock was trading at $11.04 on January 1st, 2025. Since then, EOLS stock has decreased by 42.3% and is now trading at $6.37.

Evolus, Inc. (NASDAQ:EOLS) issued its quarterly earnings data on Tuesday, March, 23rd. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.18. The business earned $20.58 million during the quarter, compared to analyst estimates of $20.60 million. Evolus had a negative trailing twelve-month return on equity of 3,474.21% and a negative net margin of 22.31%.
Read the conference call transcript
.

Evolus (EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Top institutional shareholders of Evolus include Pinnacle Associates Ltd. (1.06%), Assenagon Asset Management S.A. (0.95%), Y Intercept Hong Kong Ltd (0.40%) and Bender Robert & Associates (0.04%). Insiders that own company stock include Alphaeon 1 Llc, Medytox Inc, David Moatazedi, Rui Avelar, Vikram Malik, Sandra Beaver, Tomoko Yamagishi-Dressler, Albert G White III, David N Gill, David N Gill and Robert Hayman.
View institutional ownership trends
.

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Evolus investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
3/23/2021
Today
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EOLS
CIK
1570562
Fax
N/A
Employees
170
Year Founded
N/A

Price Target and Rating

High Price Target
$25.00
Low Price Target
$18.00
Potential Upside/Downside
+233.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.89)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$50.42 million
Net Margins
-20.40%
Pretax Margin
-20.15%
Return on Equity
-759.04%
Return on Assets
-20.14%

Debt

Debt-to-Equity Ratio
22.00
Current Ratio
2.34
Quick Ratio
2.16

Sales & Book Value

Annual Sales
$266.27 million
Price / Sales
1.54
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.09 per share
Price / Book
70.78

Miscellaneous

Outstanding Shares
64,480,000
Free Float
60,543,000
Market Cap
$410.74 million
Optionable
Optionable
Beta
1.12

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:EOLS) was last updated on 8/7/2025 by MarketBeat.com Staff
From Our Partners